康弘药业：KHN707片获准开展用于失眠症临床试验

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received approval from the National Medical Products Administration for clinical trials of KHN707 tablets, which are intended for the treatment of insomnia [1] Group 1 - The company has announced the initiation of clinical trials for KHN707 tablets [1] - The drug is specifically aimed at addressing insomnia [1] - The approval was granted by the National Medical Products Administration [1]